Positive benefit-risk ratio of Psoraleae Fructus : Comprehensive safety assessment and osteogenic effects in rats
Copyright © 2024 Elsevier B.V. All rights reserved..
ETHNOPHARMACOLOGICAL RELEVANCE: Psoraleae Fructus (PF), the dried fruit of Psoralea corylifolia L., is a commonly used traditional medicine that has contributed to the treatment of orthopedic diseases for thousands of years in China. However, recent PF-related liver injury reports have drawn widespread attention regarding its potential hepatotoxicity risks.
AIM OF THE STUDY: This study was aimed to evaluate the long-term efficacy and chronic toxicity of PF using a 26-week administration experiment on rats in order to simulate the clinical usage situation.
MATERIALS AND METHODS: The PF aqueous extract was consecutively administrated to rats daily at dosages of 0.7, 2.0, and 5.6 g/kg (equivalent to 1-8 times the clinical doses for humans) for as long as 26 weeks. Samples were collected after 13, 26, and 32 weeks (withdrawal for 6 weeks) since the first administration. The chronic toxicity of PF was evaluated by conventional toxicological methods, and the efficacy of PF was evaluated by osteogenic effects in the natural growth process.
RESULTS: In our experiments, only the H group (5.6 g/kg) for 26-week PF treatment demonstrated liver or kidney injury, which the injuries were reversible after 6 weeks of withdrawal. Notably, the PF treatment beyond 13 weeks showed significant benefits for bone growth and development in rats, with a higher benefit-risk ratio in female rats.
CONCLUSIONS: PF displayed a promising benefit-risk ratio in the treatment and prevention of osteoporosis, a disease that lacks effective medicine so far. This is the first study to elucidate the benefit-risk balance associated with clinical dosage and long-term use of PF, thereby providing valuable insights for rational clinical use and risk control of PF.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:326 |
|---|---|
| Enthalten in: |
Journal of ethnopharmacology - 326(2024) vom: 23. März, Seite 117967 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shi, Zhuo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drugs, Chinese Herbal |
|---|
| Anmerkungen: |
Date Completed 15.03.2024 Date Revised 15.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jep.2024.117967 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369209869 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369209869 | ||
| 003 | DE-627 | ||
| 005 | 20240315233506.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240304s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jep.2024.117967 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM369209869 | ||
| 035 | |a (NLM)38431111 | ||
| 035 | |a (PII)S0378-8741(24)00266-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shi, Zhuo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Positive benefit-risk ratio of Psoraleae Fructus |b Comprehensive safety assessment and osteogenic effects in rats |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2024 | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
| 520 | |a ETHNOPHARMACOLOGICAL RELEVANCE: Psoraleae Fructus (PF), the dried fruit of Psoralea corylifolia L., is a commonly used traditional medicine that has contributed to the treatment of orthopedic diseases for thousands of years in China. However, recent PF-related liver injury reports have drawn widespread attention regarding its potential hepatotoxicity risks | ||
| 520 | |a AIM OF THE STUDY: This study was aimed to evaluate the long-term efficacy and chronic toxicity of PF using a 26-week administration experiment on rats in order to simulate the clinical usage situation | ||
| 520 | |a MATERIALS AND METHODS: The PF aqueous extract was consecutively administrated to rats daily at dosages of 0.7, 2.0, and 5.6 g/kg (equivalent to 1-8 times the clinical doses for humans) for as long as 26 weeks. Samples were collected after 13, 26, and 32 weeks (withdrawal for 6 weeks) since the first administration. The chronic toxicity of PF was evaluated by conventional toxicological methods, and the efficacy of PF was evaluated by osteogenic effects in the natural growth process | ||
| 520 | |a RESULTS: In our experiments, only the H group (5.6 g/kg) for 26-week PF treatment demonstrated liver or kidney injury, which the injuries were reversible after 6 weeks of withdrawal. Notably, the PF treatment beyond 13 weeks showed significant benefits for bone growth and development in rats, with a higher benefit-risk ratio in female rats | ||
| 520 | |a CONCLUSIONS: PF displayed a promising benefit-risk ratio in the treatment and prevention of osteoporosis, a disease that lacks effective medicine so far. This is the first study to elucidate the benefit-risk balance associated with clinical dosage and long-term use of PF, thereby providing valuable insights for rational clinical use and risk control of PF | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Liver injury | |
| 650 | 4 | |a Long-term administration | |
| 650 | 4 | |a Osteogenic effects | |
| 650 | 4 | |a Psoraleae fructus | |
| 650 | 4 | |a Toxicology | |
| 650 | 7 | |a Drugs, Chinese Herbal |2 NLM | |
| 700 | 1 | |a Pan, Jin-Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Ru, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Ning-Ning |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yu-Fu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Xiang-Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Fang-Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Cui, Jia-Lu |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Chun-Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jun-Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Mao-Xing |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Cheng-Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Zeng-Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Chuan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yu-Guang |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Yue |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of ethnopharmacology |d 1980 |g 326(2024) vom: 23. März, Seite 117967 |w (DE-627)NLM00095196X |x 1872-7573 |7 nnns |
| 773 | 1 | 8 | |g volume:326 |g year:2024 |g day:23 |g month:03 |g pages:117967 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jep.2024.117967 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 326 |j 2024 |b 23 |c 03 |h 117967 | ||